Chubb in the News

Life Sciences
 

Growth Proposition, Best's Review, May 2010
The health care information technology industry presents agents and brokers with an opportunity to generate new revenue and establish themselves as risk management leaders in this developing market. Read the article or  listen to Steve Pozzi discuss this issue.

Insuring Global Clinical Trials, Pharmaceutical Executive, January 9, 2009
As clinical trial sponsors look to foreign countries to conduct clinical trials, they need to consider international regulations and laws and their potential consequences.

A Panoramic View: What Life Sciences Firms Can Learn from Insurance Carriers that Take a Holistic Approach to Underwriting, The Journal of BioLaw & Business, Vol. 10, Number 2, 2007
To really understand the risk profile of a specific biotech, underwriters must take a long-term view of the company and the exposures associated with different stages of product development.

An Ounce of Prevention, BioExecutive International, November 2006
Developing relationships with first responders can help life sciences companies keep manageable incidents from becoming costly disasters.

Critical Coverage, European Pharmaceutical Contractor, Autumn 2006
The storage of refrigerated stock is a key exposure faced by most contract manufacturing and research organizations. This article discusses how to assess and manage this critical risk.

Global Perspectives on the Life Sciences Industry , The Journal of BioLaw & Business, Vol. 9, Number 3, 2006
This article highlights the latest trends and developments in litigation, regulation, risk management and insurance that are affecting biotech companies worldwide; in addition, it includes observations about the insurance needs of biotechnology companies in the United States, Canada, Europe, Australia, Asia and Latin America.

Contingency Planning: Preparation is the Key to Recovering from Disasters , The Journal of BioLaw & Business, Vol. 9, Number 2, 2006
Businesses in any industry can reel from the repercussions of electrical outages, fires, computer hackers or the ravages of Mother Nature. When such disruptions occur, these companies may be forced to halt operations for days, weeks or even months. These businesses can and do recover, but in some sectors, like biotechnology, business interruptions that result from such events are potentially catastrophic. This article provides an overview of practical items that should be considered by all life sciences companies as part of contingency planning.

Risky Business?, European Pharmaceutical Contractor, Autumn 2005
This article by Chris Tait discusses the idea that "risk" is not always as ominous or random as the word suggests. More often than not, the risks pharmaceutical companies face can be considered, planned for and, in many cases, managed so that business can flourish.

Insuring International Clinical Trials: Navigating the Quirks and Avoiding the Quagmires, The Journal of BioLaw, Volume 8, Number 3, 2005
The recent enactment of the European Union (EU) directive on human clinical research illustrates the ever-increasing complexity of multi-site clinical research. This article discusses the importance of insurance protection against liability in international clinical trials.

Will Your Firm Be a Victim of Medical Technology Error & Omissions Litigation , The Journal of BioLaw & Business, Volume 8, Number 2, 2005
This article highlights best risk management practices for companies, with a focus on errors and omissions liability and insurance protection.

PDFs require the free Adobe Acrobat Reader. Get it here.